{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-123446","form_type":"8-K","ticker":"ANIP","cik":"0001023024","company_name":"ANI PHARMACEUTICALS INC","filed_at":"2026-11-05T22:13:17+00:00","discovered_at":"2026-11-05T22:14:00.220757+00:00","generated_at":"2026-11-05T22:14:04.947505+00:00","sec_items":["1.01","8.01","2.03","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.87,"calibrated_materiality_score":0.87,"confidence":"high","headline":"ANI to buy Egetis for ~$560M cash offer at 27% premium; EMCITATE peak sales seen above $300M","bullets":["SEK 11.25 per share cash offer values Egetis at ~SEK 5.6B ($559.9M), a 27% premium to the 60-day VWAP; enterprise value ~$434M after Egetis' $190M priority review voucher sale.","Egetis board unanimously recommends; holders of ~42.2% of outstanding shares signed irrevocables; closing needs 90% tendered plus regulatory/FDI clearances, acceptance period ~Nov 20-Dec 18, 2026.","EMCITATE (tiratricol) is the first and only approved MCT8 deficiency treatment - EU approval Feb 12, 2025, FDA Sept 28, 2026 - with >$300M peak sales potential and protection into mid-2045.","$676M 364-day senior bridge from JPMorgan (ABR+1.75%, adjusted SOFR+2.75%) funds the offer and refinances ANI's existing term loans and Egetis debt; initially unsecured, then guaranteed/secured.","ANI reports 3Q 2026 results the same morning ahead of an 8:00 a.m. ET call; Jefferies is ANI's sole financial advisor, Centerview advises Egetis, with Ropes & Gray and Mannheimer Swartling as counsel."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-123446","json":"https://secwatch.observer/filing/0001104659-26-123446.json","markdown":"https://secwatch.observer/filing/0001104659-26-123446.md","text":"https://secwatch.observer/filing/0001104659-26-123446.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1023024/000110465926123446/0001104659-26-123446-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1023024/000110465926123446/tm2628706d1_8k.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-11-05T22:14:04.947505+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}